Revolution Medicines, Inc. Total Liabilities increased by 4.2% to $753.82M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 162.5%, from $287.20M to $753.82M. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows an upward trend with a 50.8% CAGR.
A high level of total liabilities relative to equity indicates a more leveraged capital structure and higher financial risk.
The aggregate of all current and non-current debts and obligations owed by the company to external parties. It represent...
Analyzed alongside Total Assets to determine the Debt-to-Asset ratio, which is a standard measure of solvency across all industries.
total_liabilities| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $89.04M | $96.77M | $135.42M | $131.78M | $133.96M | $144.49M | $126.74M | $121.03M | $142.87M | $146.77M | $235.51M | $182.90M | $189.59M | $196.70M | $293.10M | $287.20M | $564.20M | $655.02M | $723.21M | $753.82M |
| QoQ Change | — | +8.7% | +39.9% | -2.7% | +1.7% | +7.9% | -12.3% | -4.5% | +18.0% | +2.7% | +60.5% | -22.3% | +3.7% | +3.7% | +49.0% | -2.0% | +96.4% | +16.1% | +10.4% | +4.2% |
| YoY Change | — | — | — | — | +50.5% | +49.3% | -6.4% | -8.2% | +6.7% | +1.6% | +85.8% | +51.1% | +32.7% | +34.0% | +24.5% | +57.0% | +197.6% | +233.0% | +146.7% | +162.5% |